Celltrion Pharm, Inc.

KOSDAQ 068760.KQ

Celltrion Pharm, Inc. Gross Profit Margin for the year ending December 31, 2023: 30.79%

Celltrion Pharm, Inc. Gross Profit Margin is 30.79% for the year ending December 31, 2023, a 6.45% change year over year. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.

Celltrion Pharm, Inc. Gross Profit Margin for the year ending December 31, 2022 was 28.92%, a -2.47% change year over year.
Celltrion Pharm, Inc. Gross Profit Margin for the year ending December 31, 2021 was 29.66%, a -3.39% change year over year.
Celltrion Pharm, Inc. Gross Profit Margin for the year ending December 31, 2020 was 30.70%, a -12.42% change year over year.
Celltrion Pharm, Inc. Gross Profit Margin for the year ending December 31, 2019 was 35.05%, a 31.08% change year over year.

Key data

Date	Gross Profit Margin	Operating Income Margin	EBT Margin	Net Income Margin

KOSDAQ: 068760.KQ

Celltrion Pharm, Inc.

CEO	Jung-su Seo
IPO Date	Feb. 3, 2006
Location	South Korea
Headquarters	82, 2sandan-ro
Employees	888
Sector	Health Care
Industries Pharmaceuticals Biotechnology Drugstores & Retail Pharmacies

Description

Celltrion Pharm, Inc., a pharmaceutical company, develops and sells biosimilars and over-the-counter drugs in South Korea. The company offers hepatotonic, anti-inflammatory, antihistamine, respiratory apparatus, circulary system, digestive and stomachic, hormone/metabolic disease, antibiotic/antimycotic, nutrientia and tonic, immunology, oncology, and other drugs. It serves university hospitals and general pharmacies. Celltrion Pharm Inc. was founded in 1976 and is based in Cheongju, South Korea.

Key trends

Past 5 years